Novartis Drug SOM230 Is First Medical Therapy To Show Efficacy In A Phase III Trial In Cushing's Disease, A Debilitating Hormonal Disorder
Links shared publicly online about this topic.
- 838total visits
Novartis Drug SOM230 Is First Medical Therapy To Show Efficacy In A Phase III Trial In Cushing's Disease, A Debilitating Hormonal Disorder
Novartis Pharmaceuticals Corporation (Novartis) announced that the results of a Phase III study of SOM230 (pasireotide) showed a reduction in cortisol levels in patients with Cushing's disease,
View full resource at medicalnewstoday.com
Tags: Hormone, Disease and Condition, Drug, Pharma, Novartis, disease, Medical
Most Recently Shared on September 29, 2010 at 7:05 pm By:
Novartis Drug SOM230 Is First Medical Therapy To Show Efficacy In A Phase III Trial In Cushing's Disease, A Debilitati... http://mnt.to/3KwQ
Also Shared By:
Advertisement
MNT Endocrinology
@mnt_endocrine
Novartis Drug SOM230 Is First Medical Therapy To Show Efficacy In A Phase III Trial In Cushing's Disease, A Debilitati... http://mnt.to/3KwQ
1 year ago...